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Background
The mechanism of osteoporosis in rheumatoid arthritis
(RA) is multifactorial. However, inflammation and autoim-
munity are key players in its pathogenesis. Treatment with
tumour necrosis factor alpha (TNFa) blockers has been
shown to be beneficial for bone metabolism and they were
able to prevent bone deformities in RA. Moreover, they
improved the bone mineral density (BMD) [1]. However,
the role of B lymphocytes in bone turnover is still contro-
versial. Mice models showed that B cell deficiency resulted
in marked osteopenia [2]. This was explained by the
marked decrease in bone marrow levels of osteoprotegerin
(OPG) produced by B cells. However, treatment of 46 RA
patients with rituximab revealed a marked reduction of
the bone resorption marker beta-crosslaps (bCTX) after
6 months [3].
Materials and methods
The HORUS trial aims to determine the effect of B cell
depletion on bone turnover using bone markers and bone
mineral density (BMD) measurements and to correlate
these changes with circulating B cells in RA patients trea-
ted with rituximab. Forty-five RA patients are assessed
every 3 months for one year following the administration
of their first infusion of rituximab using clinical examina-
tion, BMD measured by DXA (primary endpoint), bone
formation markers (BAP, OPG, P1NP, DKK1 and scleros-
tin), resorption markers (TRAP5b and CTX) in addition
to flow cytometry (FACS) of peripheral blood CD19+ cells
including subsets, and immunoglobulins.
Results
Forty-five RA patients have been recruited in this on-going
trial in ten UK sites. Two patients have successfully com-
pleted the study so far. Six patients have been withdrawn
from the trial. Three patients have been found to be osteo-
porotic so they had to be started on bisphosphonates. Two
patients did not have an appropriate response to rituxi-
mab. One patient developed lymphoma. A 1% increase in
BMD between baseline and 12 months is considered a sig-
nificant improvement based on a meta-analysis on anti-
resorptive agents in osteoporosis which concluded that a
1% gain in bone density of the spine was associated with a
statistically significant reduction of 8% in non-vertebral
fractures and a study in a large population cohort showing
decline of bone density over time in RA patients not trea-
ted with anti-resorptive agents [4].
Conclusion
The HORUS trial examines the effects of rituximab on
markers of bone turnover and bone mass in RA. This will
help determine whether B cells play a role in RA asso-
ciated bone loss.
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